Pfizer (NYSE:PFE) Stock Price Down 1.5% – What’s Next?

Pfizer Inc. (NYSE:PFE) shares fell 1.5% on Tuesday . The company traded as low as $22.31 and last traded at $22.28. 21,090,454 shares were traded during trading, a decline of 47% from the average session volume of 39,584,296 shares. The stock had previously closed at $22.63.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.43.

Pfizer Price Performance

The firm has a market capitalization of $123.96 billion, a P/E ratio of 15.50, a PEG ratio of 0.64 and a beta of 0.67. The business’s 50-day simple moving average is $25.79 and its 200 day simple moving average is $26.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter worth about $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.